Trial · NCT00450619
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients With Stable Disease at 4 Months. | 4.7 months | participants | NUMBER | |
| PRIMARY | Progression Free Survival (PFS) | 4 months | months | MEDIAN | |
| SECONDARY | Toxicity | 5 years, 5 months | Participants | NUMBER | |
| SECONDARY | Number of Participants With Prostate-Specific Antigen (PSA) ≥ 30% | 4 months | participants | NUMBER | |
| SECONDARY | Number of Participants With Prostate-Specific Antigen (PSA) ≥50% | 4 months | participants | NUMBER | |
| SECONDARY | Overall Survival | From date of randomization until death or last follow up, whichever comes first, assessed up to 14 months. | Months | MEDIAN | |
| SECONDARY | Arm A: Prostate-Specific Antigen (PSA) T-cell Responses Post-vs. Pre-treatment | Approximately 60 days | (a)Cytokine or CD107a in CD4 or CD8. \*Pts displayed pre-existing PSA-specific T-cell responses. Numbers 274, 630, and 1427 are those positive post- vs. pre-vaccination. Absolute # CD4 or CD8 producing cytokine/CD107a+/1x10(6) cells plated at start of in vitro stimulation. | Absolute # CD4 or CD8 producing cytokine | NUMBER |
| SECONDARY | Arm B: Prostate-Specific Antigen (PSA) T-cell Responses Post-vs. Pre-treatment | Approximately 60 days | (a)Cytokine or CD107a in CD4 or CD8. \*Pts displayed pre-existing PSA-specific T-cell responses. Numbers 786, 374, 345, 402, 821, 815, 5269, 453, 633, 1242 \& 0 for PT 2 CD4/CD8 IL2 \& 0 for PT 16 TNF are those positive post- vs. pre-vaccination. Absolute # CD4 or CD8 producing cytokine/CD107a+/1x10(6) cells plated at start of in vitro stimulation. | Absolute # CD4 or CD8 producing cytokine | NUMBER |
| SECONDARY | Objective Response (Complete Response + Partial Response) | 4 weeks | Not all participants was measureable by RECIST. | participants | NUMBER |
| SECONDARY | Palliation: Pain at Baseline | Baseline | participants | NUMBER | |
| SECONDARY | Palliation: Improvement in Baseline Pain | post quadramet (samarium) | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00450619/outcomes